UHS Universal Health Services (UHS) Insider Trading, Ownership & Congress Trades
Healthcare Services · Services-general medical & surgical hospitals, nec · CIK 0000352915
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
0
13F, latest reported quarter
What the filings say about UHS
Congress, 1 year
No trades
Last one: purchase, 2025-10-23
Universal Health Services insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
No insider purchases or sales are on record for UNIVERSAL HEALTH SERVICES INC in the period covered. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
Context
- 5 earlier Form 4 trades (code P or S) here by this insider (5 sales), the last on Mar 11, 2026.
- The trade is 5.8% of the 6,113 shares held after it.
- No other insider sold within 30 days.
Insider activity: Director SUSSMAN ELLIOT J MD MBA sold about $68.8K of UHS on Mar 13, 2026.Context
- 4 earlier Form 4 trades (code P or S) here by this insider (4 sales), the last on Oct 29, 2025.
- The trade is 5.2% of the 6,113 shares held after it.
- No other insider sold within 30 days.
Insider activity: Director SUSSMAN ELLIOT J MD MBA sold about $59.3K of UHS on Mar 11, 2026.Context
- 4 earlier Form 4 trades (code P or S) here by this insider (4 sales), the last on Aug 12, 2024.
- The trade is 1.7% of the 8,481 shares held after it.
- 1 other insider sold within 30 days.
Insider activity: Director Nimetz Warren J. sold about $31.8K of UHS on Nov 11, 2025; 1 other insider sold within 30 days.Context
- 4 earlier Form 4 trades (code P or S) here by this insider (4 sales), the last on Aug 12, 2024.
- The trade is 42.6% of the 8,623 shares held after it.
- 1 other insider sold within 30 days.
Insider activity: Director Nimetz Warren J. sold about $820.6K of UHS on Nov 11, 2025, the largest insider sale at the company since 2024; 1 other insider sold within 30 days.Context
- 3 earlier Form 4 trades (code P or S) here by this insider (3 sales), the last on Aug 13, 2024.
- The trade is 15.8% of the 6,113 shares held after it.
- 1 other insider sold within 30 days.
Insider activity: Director SUSSMAN ELLIOT J MD MBA sold about $217.8K of UHS on Oct 29, 2025; 1 other insider sold within 30 days.42 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
no insider buys or sells on file
Congress
no House purchase disclosed in the last 12 months
Funds
under five funds report holding it
Revenue
+9.7% year over year
below 55% of Healthcare Services
Margin
8.6% net margin
more than 84% of Healthcare Services
Buybacks
$484.6M repurchased, FY to 2026-06-30
more than 94% of Healthcare Services
Short interest
5.2% of the float short (float per yahoo 2026-10-26) · 2.8 days to cover · settled 2026-09-30
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch UHS
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-14.7%12M
Insider sell
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns UHS: institutional holders (13F)
13F holdings, latest reported quarter
SEC 13F
No reported 13F holders
No fund above the reporting threshold listed this stock last quarter. That is a fact, not missing data.
Congress trades in UHS
STOCK Act disclosures, US House only, filed up to 45 days after the trade
Bought 2025-10-23 · disclosed 82 days later
$1,001 - $15,000
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
UHS planned insider sales (Form 144)
No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
Each figure here is a federal filing, dated the day it went public, so you can test what was knowable then.
UHS financials
Revenue growth
+9.7%
XBRL, annual
Net margin
8.6%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$18.1B
four quarters, 2025-07-01 to 2026-06-30
Revenue, TTM UHS
| FY Dec 2025 | $17.4B |
| FY Dec 2024 | $15.8B |
| FY Dec 2023 | $14.3B |
| FY Dec 2022 | $13.4B |
| FY Dec 2021 | $12.6B |
| Jun 2026 | $4.6B |
| Mar 2026 | $4.5B |
| Dec 2025 | $4.5B |
| Sep 2025 | $4.5B |
| Jun 2025 | $4.3B |
| Mar 2025 | $4.1B |
| Dec 2024 | $4.1B |
| Sep 2024 | $4.0B |
At each fiscal year end
Single quarter
Net margin, TTM
+8.4%
net income over revenue, 2025-07-01 to 2026-06-30
Net margin, TTM UHS
| FY Dec 2025 | +8.6% |
| FY Dec 2024 | +7.2% |
| FY Dec 2023 | +5.0% |
| FY Dec 2022 | +5.0% |
| FY Dec 2021 | +7.8% |
| Jun 2026 | +7.7% |
| Mar 2026 | +7.8% |
| Dec 2025 | +9.9% |
| Sep 2025 | +8.3% |
| Jun 2025 | +8.2% |
| Mar 2025 | +7.7% |
| Dec 2024 | +8.1% |
| Sep 2024 | +6.5% |
At each fiscal year end
Single quarter
Free cash flow, TTM
$845.4M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM UHS
| FY Dec 2025 | $849.2M |
| FY Dec 2024 | $1.1B |
| FY Dec 2023 | $524.7M |
| FY Dec 2022 | $262.0M |
| FY Dec 2021 | $28.0M |
| Jun 2026 | $215.7M |
| Mar 2026 | $184.5M |
| Dec 2025 | $293.5M |
| Sep 2025 | $151.8M |
| Jun 2025 | $283.0M |
| Mar 2025 | $121.0M |
| Dec 2024 | $412.5M |
| Sep 2024 | $85.0M |
At each fiscal year end
Single quarter
Debt to equity
0.65x
long-term 2026-06-30 plus current 2026-06-30; equity 2026-06-30
Debt to equity UHS
| FY Dec 2025 | 0.65x |
| FY Dec 2024 | 0.68x |
| FY Dec 2023 | 0.80x |
| FY Dec 2022 | 0.81x |
| FY Dec 2021 | 0.69x |
| Jun 2026 | 0.65x |
| Mar 2026 | 0.63x |
| Dec 2025 | 0.65x |
| Sep 2025 | 0.65x |
| Jun 2025 | 0.65x |
| Mar 2025 | 0.69x |
| Dec 2024 | 0.68x |
| Sep 2024 | 0.70x |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
0.37x
TTM operating cash flow over long-term 2026-06-30 plus current 2026-06-30
Cash flow to debt UHS
| FY Dec 2025 | 0.39x |
| FY Dec 2024 | 0.46x |
| FY Dec 2023 | 0.26x |
| FY Dec 2022 | 0.21x |
| FY Dec 2021 | 0.21x |
| Jun 2026 | 0.37x |
| Mar 2026 | 0.40x |
| Dec 2025 | 0.39x |
| Sep 2025 | 0.42x |
| Jun 2025 | 0.41x |
| Mar 2025 | 0.44x |
| Dec 2024 | 0.46x |
| Sep 2024 | 0.40x |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
+21.0%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity UHS
| FY Dec 2025 | +21.4% |
| FY Dec 2024 | +17.8% |
| FY Dec 2023 | +11.9% |
| FY Dec 2022 | +11.3% |
| FY Dec 2021 | +16.0% |
| Jun 2026 | +21.0% |
| Mar 2026 | +21.3% |
| Dec 2025 | +21.4% |
| Sep 2025 | +20.0% |
| Jun 2025 | +18.7% |
| Mar 2025 | +18.4% |
| Dec 2024 | +17.8% |
| Sep 2024 | +16.2% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
+9.9%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets UHS
| FY Dec 2025 | +9.9% |
| FY Dec 2024 | +8.0% |
| FY Dec 2023 | +5.2% |
| FY Dec 2022 | +5.1% |
| FY Dec 2021 | +7.5% |
| Jun 2026 | +9.9% |
| Mar 2026 | +10.0% |
| Dec 2025 | +9.9% |
| Sep 2025 | +9.3% |
| Jun 2025 | +8.7% |
| Mar 2025 | +8.3% |
| Dec 2024 | +8.0% |
| Sep 2024 | +7.3% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
+13.1%
operating income after a 23.5% effective tax rate, over long-term 2026-06-30 plus current 2026-06-30 plus average of 2025-06-30 and 2026-06-30 minus cash
Return on invested capital UHS
| FY Dec 2025 | +13.2% |
| FY Dec 2024 | +12.1% |
| FY Dec 2023 | +8.3% |
| FY Dec 2022 | +7.1% |
| FY Dec 2021 | +10.7% |
| Jun 2026 | +13.1% |
| Mar 2026 | +13.4% |
| Dec 2025 | +13.2% |
| Sep 2025 | +13.0% |
| Jun 2025 | +12.4% |
| Mar 2025 | +12.2% |
| Dec 2024 | +12.1% |
| Sep 2024 | +11.0% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
+16.3%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed UHS
| FY Dec 2025 | +16.2% |
| FY Dec 2024 | +13.9% |
| FY Dec 2023 | +10.0% |
| FY Dec 2022 | +8.8% |
| FY Dec 2021 | +12.3% |
| Jun 2026 | +16.3% |
| Mar 2026 | +16.3% |
| Dec 2025 | +16.2% |
| Sep 2025 | +15.9% |
| Jun 2025 | +14.7% |
| Mar 2025 | +14.3% |
| Dec 2024 | +13.9% |
| Sep 2024 | +12.7% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
7.23x
close 2026-10-27 over four quarters of diluted EPS, 2025-07-01 to 2026-06-30
P/E, trailing UHS
| FY Dec 2025 | 9.43x |
| FY Dec 2024 | 10.67x |
| FY Dec 2023 | 14.89x |
| FY Dec 2022 | 15.40x |
| FY Dec 2021 | 10.98x |
| Jun 2026 | 6.06x |
| Mar 2026 | 7.47x |
| Dec 2025 | 9.43x |
| Sep 2025 | 9.72x |
| Jun 2025 | 9.55x |
| Mar 2025 | 10.56x |
| Dec 2024 | 10.67x |
| Sep 2024 | 15.25x |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
n/a
no share count filed
Enterprise value UHS
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
n/a
no share count filed
FCF yield UHS
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
0.25x
P/E over trailing EPS growth of 29%: four quarters to 2026-06-30 against the four to 2025-06-30
PEG, trailing UHS
| FY Dec 2025 | 0.25x |
| FY Dec 2024 | 0.17x |
| FY Dec 2023 | 1.25x |
| FY Dec 2022 | n/a |
| FY Dec 2021 | 1.51x |
| Jun 2026 | 0.21x |
| Mar 2026 | 0.22x |
| Dec 2025 | 0.25x |
| Sep 2025 | 0.24x |
| Jun 2025 | 0.24x |
| Mar 2025 | 0.21x |
| Dec 2024 | 0.17x |
| Sep 2024 | 0.26x |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-27. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $17.4B | $15.8B | $14.3B | $13.4B |
| Operating income | $2.0B | $1.7B | $1.2B | $1.0B |
| Net income | $1.5B | $1.1B | $717.8M | $675.6M |
| EPS (diluted) | 23.10 | 16.82 | 10.23 | 9.14 |
| Operating cash flow | $1.9B | $2.1B | $1.3B | $996.0M |
| Cash | $137.8M | $126.0M | $119.4M | $102.8M |
| Long-term debt | $4.0B | $4.5B | $4.8B | $4.7B |
| Buybacks | $968.0M | $670.8M | $547.4M | $832.9M |
| Dividends paid | $51.3M | $53.3M | $55.5M | $58.4M |
SEC XBRL, fiscal years, as known on 2026-10-28
UHS Stock Sonar score 4/7 axes
Find similar shapesCompareUHS ranks highest on profitability (80th percentile) and financial health (57th), and lowest on growth (45th), among Healthcare Services peers.
4 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
UHS filings, in plain words
Have members of Congress traded UHS?
Yes, but not in the year to 2026-10-28; the latest on record is a purchase by Julia Letlow dated 2025-10-23.
Read the full summary
Members of Congress have disclosed trades in UHS, none in the last year; the latest on record is a purchase by Julia Letlow dated 2025-10-23. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
